Stenotrophomonas maltophilia (S. maltophilia)

Stenotrophomonas maltophilia is a Gram-negative, non-fermenting, aerobic bacillus that functions as a significant opportunistic human pathogen, primarily in hospital settings and among immunocompromised patients (Brooke, 2012; PMID: 22433324). While not a single molecular target such as a receptor or enzyme, it is a critical clinical target for specialized antimicrobial therapy due to its remarkable intrinsic resistance to many broad-spectrum antibiotics, including carbapenems (StatPearls, 2023; NBK534241). The organism is frequently associated with respiratory tract infections, particularly in patients with cystic fibrosis or those requiring mechanical ventilation, as well as catheter-related bacteremia. Its survival and virulence are enhanced by the production of extracellular enzymes and the ability to form dense biofilms on surfaces like plastic catheters and endotracheal tubes (NCBI, 2021). Treatment is challenging and typically necessitates agents such as trimethoprim-sulfamethoxazole, though the emergence of resistance mediated by efflux pumps and metallo-beta-lactamases remains a major therapeutic concern (Cai et al., 2020; PMID: 32694114). Effective management often requires susceptibility testing and, in some cases, combination therapy to overcome its complex defense mechanisms.

Other names

Pseudomonas maltophiliaXanthomonas maltophiliaBacterium maltophilia

Drugs targeting this organism typically inhibit bacterial cell wall synthesis (beta-lactams/beta-lactamase inhibitors), disrupt DNA replication by targeting DNA gyrase and topoisomerase IV (fluoroquinolones), or inhibit the folic acid synthesis pathway (sulfonamides and trimethoprim).